Medicalgorithmics S.A.

Medicalgorithmics S.A. specialises in electrocardiographic (ECG) monitoring devices. Their products include portable ambulatory recorders for long-term cardiac rhythm analysis, such as the PocketECG series and Q Patch systems. These devices are designed for telemetric ECG transmission, including single-use and reusable patch-based solutions, as well as software applications like the Medicalgorithmics Unified Arrhythmia Diagnostic System for analysing recorded arrhythmias. The focus is on portable, diagnostic tools for cardiac monitoring.

Medicalgorithmics S.A. is based in the United States. Their devices fall under the FDA’s Class II classification, which typically requires premarket authorisation. The company’s products are authorised through pathways like the 510(k) premarket notification process or De Novo classification, depending on the device’s innovation level. This means each device must meet FDA requirements for safety and effectiveness before entering the market.

Medicalgorithmics S.A.’s devices are included in the FDA’s official registries, specifically the 510(k) premarket notification database and the Unique Device Identification (UDI) system. These registries track authorised medical devices in the U.S., ensuring transparency and compliance with regulatory requirements. Listing in these databases confirms that the devices have undergone the necessary FDA review processes.

Medicalgorithmics S.A.’s ECG monitoring devices are classified as Class II under the U.S. FDA’s regulatory framework. Class II devices generally pose moderate risk and require special controls to ensure safety and performance, such as premarket notifications (510(k)) or De Novo pathways. This classification reflects the need for rigorous evaluation before these diagnostic tools can be authorised for use in clinical settings.